Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

Volume: 187, Issue: 5, Pages: 980 - 986
Published: May 1, 2017
Abstract
Inhibition of the Janus kinase (JAK)-STAT pathway has been implicated as a treatment option for extranodal natural killer/T-cell lymphoma, nasal type (NTCL). However, JAK-STAT pathway alterations in NTCL are variable, and the efficacy of JAK-STAT pathway inhibition has been poorly evaluated. JAK3 mutation and STAT3 genetic alterations were investigated by direct sequencing and immunohistochemistry in 84 patients with newly diagnosed NTCL. Five...
Paper Details
Title
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
Published Date
May 1, 2017
Volume
187
Issue
5
Pages
980 - 986
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.